Effect of Q10 on multiple sclerosis patients
Phase 3
- Conditions
- multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT138905172602N4
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
age 18-51 years, able to provide informed consent and diagnosed with relapsing remitting MS. Exclusion criteria: MS exacerbation during the study, systemically administered corticosteroids during the study , pregnant or breast-feeding , other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus and other autoimmune disease) that might increase the risk of subject experiencing adverse events. Consumption of vitamin, mineral and antioxidant supplement 30 days before study entry, Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study and compliance less than 70%.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TGF-B. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.;Serum TNF-a concentration. Timepoint: 12 weeks after the intervention. Method of measurement: labratory kit.;IL-4. Timepoint: 12 weeks after the intervention. Method of measurement: ELYSA.;IL-6. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.;MMP-9. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method